Published in Blood Weekly, April 1st, 1996
Under the agreement, HemaSure is a licensing agent for DRK's patented methylene blue technology for the inactivation of lipid-enveloped viruses in transfusion plasma. The agreement grants DRK an option to enter into a separate contract for the purchase and sale of HemaSure's LeukoVir-MB Filter, designed to remove methylene blue and leukocytes from transfusion plasma.
"Methylene blue technology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.